AAAAAA

   
Results: 1-9 |
Results: 9
EFAROXAN, AN ALPHA-2 ANTAGONIST, IN THE TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
Authors: RASCOL O SIERADZAN K PEYROSAINTPAUL H THALAMAS C BREFELCOURBON C SENARD JM LADURE P MONTASTRUC JL LEES A
Citation: O. Rascol et al., EFAROXAN, AN ALPHA-2 ANTAGONIST, IN THE TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY, Movement disorders, 13(4), 1998, pp. 673-676
APOMORPHINE RESPONSES IN PARKINSONS-DISEASE AND THE PATHOGENESIS OF MOTOR COMPLICATIONS
Authors: COLOSIMO C MERELLO M HUGHES AJ SIERADZAN K LEES AJ
Citation: C. Colosimo et al., APOMORPHINE RESPONSES IN PARKINSONS-DISEASE AND THE PATHOGENESIS OF MOTOR COMPLICATIONS, Neurology, 50(2), 1998, pp. 573-574
CLINICAL PRESENTATION AND PATTERNS OF REGIONAL CEREBRAL ATROPHY RELATED TO THE LENGTH OF TRINUCLEOTIDE REPEAT EXPANSION IN PATIENTS WITH ADULT-ONSET HUNTINGTONS-DISEASE
Authors: SIERADZAN K MANN DMA DODGE A
Citation: K. Sieradzan et al., CLINICAL PRESENTATION AND PATTERNS OF REGIONAL CEREBRAL ATROPHY RELATED TO THE LENGTH OF TRINUCLEOTIDE REPEAT EXPANSION IN PATIENTS WITH ADULT-ONSET HUNTINGTONS-DISEASE, Neuroscience letters, 225(1), 1997, pp. 45-48
IDIOPATHIC PARKINSONS-DISEASE - EPIDEMIOLOGY, DIAGNOSIS AND MANAGEMENT
Authors: BENSHLOMO Y SIERADZAN K
Citation: Y. Benshlomo et K. Sieradzan, IDIOPATHIC PARKINSONS-DISEASE - EPIDEMIOLOGY, DIAGNOSIS AND MANAGEMENT, British journal of general practice, 45(394), 1995, pp. 261-268
THE THERAPEUTIC POTENTIAL OF MOCLOBEMIDE, A REVERSIBLE SELECTIVE MONOAMINE-OXIDASE-A INHIBITOR IN PARKINSONS-DISEASE
Authors: SIERADZAN K CHANNON S RAMPONI C STERN GM LEES AJ YOUDIM MBH
Citation: K. Sieradzan et al., THE THERAPEUTIC POTENTIAL OF MOCLOBEMIDE, A REVERSIBLE SELECTIVE MONOAMINE-OXIDASE-A INHIBITOR IN PARKINSONS-DISEASE, Journal of clinical psychopharmacology, 15(4), 1995, pp. 51-59
STIMULATION AND RECORDING FROM THE NUCLEUS-VENTRALIS-INTERMEDIUS (VIM) IN A PATIENT WITH PARKINSONS-DISEASE
Authors: ROTHWELL JC BRANSTON N CORCOS D ASSELMAN P SIERADZAN K THOMAS D
Citation: Jc. Rothwell et al., STIMULATION AND RECORDING FROM THE NUCLEUS-VENTRALIS-INTERMEDIUS (VIM) IN A PATIENT WITH PARKINSONS-DISEASE, Journal of physiology, 483P, 1995, pp. 32-32
EXPRESSION OF CHOLINERGIC PHENOTYPE BY EMBRYONIC VENTRAL HORN NEURONSTRANSPLANTED INTO THE SPINAL-CORD IN THE RAT
Authors: CLOWRY GJ SIERADZAN K VRBOVA G
Citation: Gj. Clowry et al., EXPRESSION OF CHOLINERGIC PHENOTYPE BY EMBRYONIC VENTRAL HORN NEURONSTRANSPLANTED INTO THE SPINAL-CORD IN THE RAT, Restorative neurology and neuroscience, 6(3), 1994, pp. 209-219
OBSERVATIONS ON THE SURVIVAL OF GRAFTED EMBRYONIC MOTONEURONS IN THE SPINAL-CORD OF DEVELOPING RATS
Authors: SIERADZAN K VRBOVA G
Citation: K. Sieradzan et G. Vrbova, OBSERVATIONS ON THE SURVIVAL OF GRAFTED EMBRYONIC MOTONEURONS IN THE SPINAL-CORD OF DEVELOPING RATS, Experimental neurology, 122(2), 1993, pp. 223-231
THE ABILITY OF DEVELOPING SPINAL NEURONS TO REINNERVATE A MUSCLE THROUGH A PERIPHERAL-NERVE CONDUIT IS ENHANCED BY COGRAFTED EMBRYONIC SPINAL-CORD
Authors: SIERADZAN K VRBOVA G
Citation: K. Sieradzan et G. Vrbova, THE ABILITY OF DEVELOPING SPINAL NEURONS TO REINNERVATE A MUSCLE THROUGH A PERIPHERAL-NERVE CONDUIT IS ENHANCED BY COGRAFTED EMBRYONIC SPINAL-CORD, Experimental neurology, 122(2), 1993, pp. 232-243
Risultati: 1-9 |